Related references
Note: Only part of the references are listed.Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
Neeraj Gupta et al.
CLINICAL PHARMACOKINETICS (2021)
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial
Xiaofei Zhou et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Effect of severe renal impairment on the pharmacokinetics of brigatinib
Neeraj Gupta et al.
INVESTIGATIONAL NEW DRUGS (2021)
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Rudolf M. Huber et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study
Neeraj Gupta et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer
Joachim Grevel et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients
Yvonne Y. Lau et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Meera Tugnait et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Peter N. Morcos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development
Stephanie Faucette et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Neeraj Gupta et al.
TARGETED ONCOLOGY (2017)
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Qian Zhu et al.
BMC CANCER (2017)
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
Dan Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
K. Venkatakrishnan et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities
K. Venkatakrishnan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Share Paper
